Zura Bio Ltd

Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company focused on immunological diseases that entered the public markets through a business combination with JAWS Healthcare Innovators Acquisition Corp, a blank-check vehicle that completed its initial public offering in 2021 and was sponsored by JAWS Healthcare Management LLC. The Form 10-Q filed on November 14, 2022 reflects the company's quarterly reporting obligations as a post-merger public entity operating in the life sciences and healthcare sector. Zura Bio's pipeline targets autoimmune conditions, consistent with the broader clinical-stage biotech profile that characterized many SPAC combinations during the 2020–2022 wave. To access full filing histories, sponsor profiles, and deal-level data on ZURA and thousands of other SPAC transactions, sign up for a SpacDesk account today.